- Previous Close
3.9800 - Open
4.0550 - Bid 4.0100 x 100
- Ask 4.1900 x 100
- Day's Range
3.8801 - 4.1500 - 52 Week Range
1.8000 - 20.8300 - Volume
61,864 - Avg. Volume
139,271 - Market Cap (intraday)
15.101M - Beta (5Y Monthly) -0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-43.2200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
25.50
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
www.cingulate.comRecent News: CING
View More
Performance Overview: CING
Trailing total returns as of 3/26/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CING
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CING
View MoreValuation Measures
Market Cap
15.10M
Enterprise Value
5.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.25
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-104.33%
Return on Equity (ttm)
-273.82%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.35M
Diluted EPS (ttm)
-43.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
10.04M
Total Debt/Equity (mrq)
1.95%
Levered Free Cash Flow (ttm)
-10.12M
Research Analysis: CING
View MoreCompany Insights: CING
CING does not have Company Insights